LicianPro

TEVA stock

Teva Pharmaceutical Industries (TEVA) institutional holders · P/E 91, rev $17.26B

Teva Pharmaceutical Industries institutional holders from SEC Form 13F, top 3 by reported value. Each row is the filer's newest 13F for quarters ended 2026-06-30 or later, share lines summed, options excluded; value is the 13F-reported market value in US dollars. Rows marked Prior quarter are filers whose 2026-09-30 13F is not cached yet.

Institutional holders · SEC Form 13F
HolderSharesValueReport
FMR LLC30,258,016$1.03B2026-06-30Prior quarter
STATE STREET CORP18,936,548$641.6M2026-06-30Prior quarter
Bridgewater Associates, LP1,326,678$44.9M2026-06-30Prior quarter
These 13F holders as JSON? API free 100/day

TEVA institutional holders FAQ

What is TEVA's P/E ratio?

Teva Pharmaceutical Industries (TEVA) trailing P/E is 91.2 on the latest cached fundamentals snapshot.

What is TEVA's latest revenue?

Latest cached Teva Pharmaceutical Industries (TEVA) revenue for Dec 31, 2025 was $17.26B. Statements: https://lician.com/financials/teva

Not investment advice. Figures as filed or reported, not a live feed.